Raymond James Upgrades Oncolytics Biotech (TSE:ONC) to “Moderate Buy”

Raymond James upgraded shares of Oncolytics Biotech (TSE:ONC) to a moderate buy rating in a research note published on Thursday morning,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.47) EPS.

Oncolytics Biotech Trading Down 2.1 %

Shares of ONC stock traded down C$0.03 on Thursday, reaching C$1.38. 95,200 shares of the stock were exchanged, compared to its average volume of 71,027. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86. Oncolytics Biotech has a one year low of C$1.15 and a one year high of C$2.32. The stock has a market cap of C$106.07 million, a PE ratio of -3.63 and a beta of 1.35. The stock has a 50 day moving average price of C$1.50 and a 200 day moving average price of C$1.45.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.